

20 CRISPR patents granted to the Life Science business of Merck KGaA, Darmstadt, Germany

Leading the way in genome-editing technology

CRISPR Integration:

CRISPR/Cas9 System for Insertion in Eukaryotic Cells

Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA

Patents Received

● 2017 ○ 2018 ▲ 2019

▨ Patents Pending

proxy-CRISPR:

New genome-editing technique that makes CRISPR more efficient, flexible and specific

Opens up the genome for modification of DNA, providing more experimental options, faster results

Patents Received

▲ 2019

▨ Patents Pending

Paired Nickase:

Cleavage of Chromosomal Sequences using Dual Nickases

Compositions and use of two Cas9 nickases to cut genomic DNA, optionally followed by integration of new DNA sequence

Patents Received

○ 2018 ▲ 2019

▨ Patents Pending



The businesses of Merck KGaA, Darmstadt, Germany operate as EMD Serono, MilliporeSigma and EMD Performance Materials in the U.S. and Canada